The Rising Importance of Minor Cannabinoids in the Growing Edible Market

The cannabis industry is witnessing a notable shift towards edibles infused with minor cannabinoids, a trend underscored by a recent report from BayMedica, a subsidiary of InMed Pharmaceuticals. This shift is part of a broader 5.4% revenue surge in the edible market, which reached $2.097 billion in 2023, with minor cannabinoid-infused edibles alone accounting for $391 million, marking a 47% year-over-year growth.

Minor cannabinoids, such as Cannabichromene (CBC), Tetrahydrocannabivarin (THCV), Cannabidivarin (CBDV), and Cannabinol (CBN), are gaining traction for their unique properties and potential health benefits. Unlike THC and CBD, these compounds are found in smaller quantities in cannabis plants but offer a range of effects from mood enhancement to appetite suppression and pain relief, contributing to their growing popularity among consumers.

The report highlights that 24 of the top 50 selling edibles in 2023 incorporated minor cannabinoids, reflecting a significant market trend. Brands leveraging these compounds are able to command a premium, with products priced 6.3% higher on average than those with standard THC formulations. This premium is attributed to the perceived value and therapeutic benefits of minor cannabinoids, including the entourage effect, which suggests that cannabinoids work synergistically to enhance each other's effects.

Commercial adoption of minor cannabinoids is also evolving, with CBN leading in sales due to its potential sedative effects, while THCV experienced a 140% year-over-year growth, driven by its appetite-suppressing and energy-boosting properties. The accessibility of these compounds has improved, thanks to advancements in biosynthesis and synthetic chemistry, enabling their production at commercial scales.

As the edible market continues to grow, the focus on minor cannabinoids represents a paradigm shift towards more targeted therapeutic effects and consistent consumer experiences. This trend not only highlights the evolving priorities of cannabis consumers but also opens new avenues for innovation and differentiation in a competitive market. With companies like BayMedica at the forefront of scaling operations and expanding product offerings, the future of minor cannabinoids in edibles looks promising, paving the way for a new era in holistic well-being.